Patient-derived tumor organoids to model drug response in gastric cancer

Anette Vistoso Monreal; Hua Zhao; Parish P Sedghizadeh; De-Chen Lin

doi:10.1016/j.xcrm.2024.101650

Patient-derived tumor organoids to model drug response in gastric cancer

Cell Rep Med. 2024 Jul 16;5(7):101650. doi: 10.1016/j.xcrm.2024.101650.

Authors

Anette Vistoso Monreal¹, Hua Zhao², Parish P Sedghizadeh³, De-Chen Lin⁴

Affiliations

¹ Department of Diagnostic Sciences, Anesthesia & Emergency Medicine, Infection and Immunity Laboratory, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.
² Center for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.
³ Department of Diagnostic Sciences, Anesthesia & Emergency Medicine, Infection and Immunity Laboratory, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA. Electronic address: sedghiza@usc.edu.
⁴ Center for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA. Electronic address: dechenli@usc.edu.

Abstract

Gastric cancer poses diverse treatment challenges due to its high tumor heterogeneity. Through the use of patient-derived tumor organoid (PDO) models, new research¹ has identified genes and molecular signatures that are predictive of chemotherapeutic response, providing valuable insights for clinical management and translational advancements.

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
Humans
Organoids* / drug effects
Organoids* / metabolism
Organoids* / pathology
Stomach Neoplasms* / drug therapy
Stomach Neoplasms* / genetics
Stomach Neoplasms* / metabolism
Stomach Neoplasms* / pathology

Substances

Antineoplastic Agents

Abstract

MeSH terms

Substances

Grants and funding